Published date:Apr 16 2019

Journal Title: KnE Engineering

Issue title: International Conference on Basic Sciences and Its Applications (ICBSA-2018)

Pages:329–336

DOI: 10.18502/keg.v1i2.4457

Muhammad Yulis Hamidy

Fadil Oenzil

Yanwirasti .

Yufri Aldi

Atherosclerosis is a chronic inflammatory disease that is caused by multiple processes. Inflammation is the main mechanism underlying the pathogenesis of atherosclerosis. The initiation stage of atherosclerosis is characterized by the formation of foam cells. Andrographolide is a compound that has an anti-inflammatory effect that is expected to be used as an anti-atherosclerosis. The purpose of this study was to evaluate andrographolide effect on foam cell formation at the initiation stage of atherosclerosis. The study was conducted on 27 rats divided into 3 groups (n=9). Group 1 was given a normal diet. Group 2 was given an atherogenic diet (vitamin D3 700,000 IU/kg on the first day and 2% cholesterol, 5% goat fat, 0.2% cholic acid and standard diet up to 100% for 2 days). Group 3 was given an atherogenic diet and andrographolide 40 mg/kg. The andrographolide effect on foam cell formation was assessed by histopathologic examination using hematoxylin eosin staining. The results showed that the number of foam cells was increased significantly in atherogenic diet-fed rats compared to normal diet-fed rats (82.33 + 13.10 vs. 5.33 + 1.73; P<0,05). Andrographolide reduced this number remarkably (82.33 + 13.10 vs. 7.44 + 1.62; P<0,05). In conclusion, andrographolide inhibits the formation of foam cells at the initiation stage of atherosclerosis. Thus andrographolide can be potentially developed as an anti-atherosclerosis.

Keywords: andrographolide, foam cell, atherosclerosis

[1] Libby P. et al. (2010). Inflammation in atherosclerosis: transition from theory to practice, Circulation Journal. 74:213-20l.


[2] Hansson GK. (2005). Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med. 352:1685-95.


[3] Chistiakov DA. et al. (2016). Macrophage-mediated cholesterol handling in atherosclerosis, J. Cell. Mol. Med. 20(1): 17-28.


[4] Colin S. et al. (2014). Macrophage phenotypes in atherosclerosis, Immunol Rev. 262: 153–66.


[5] Collot-Teixeira S. et al. (2007). CD36 and macrophages in atherosclerosis, Cardiovasc Res. 75:468–77.


[6] Bobryshev YV. (2006). Monocyte recruitment and foam cell formation in atherosclerosis, Micron. 37: 208–22.


[7] Low M. et al. (2015). An in vitro study of anti-inflammatory activity of standardised Andrographis paniculata extracts and pure andrographolide, BMC Complementary and Alternative Medicine. 2015; 15:18.


[8] Liu J. et al. (2007). Inhibitory effects of neoandrographolide on nitric oxide and prostaglandin E2 production in LPS-stimulated murine macrophage, Mol Cell Biochem. 298:49–57.


[9] Shen T. et al. (2013). AP-1/irf-3 targeted anti-inflammatory activity of andrographolide isolated from Andrographis paniculata, Evidence-Based Complementary and Alternative Medicine. article ID 210736.


[10] Luo W. et al. (2013). Andrographolide inhibits the activation of NF-κB and MMP-9 activity in H3255 lung cancer cells, Experimental and Therapeutic Medicine. 6:743- 6.


[11] Ren J. et al. (2016). Andrographolide ameliorates abdominal aortic aneurysm progression by inhibiting inflammatory cell infiltration through downregulation of cytokine and integrin expression, J Pharmacol Exp Ther. 356(1):137-47.


[12] Pang J. et al. (2010). Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat, Peptides. 31:630-8.


[13] Murwani S. et al. (2006). Diet aterogenik pada tikus putih (Rattus norvegicus) strain wistar sebagai model hewan aterosklerosis, Jurnal Kedokteran Brawijaya. 22:6-12.


[14] Ismawati. et al. (2016). Changes in expression of proteasome in rats at different stages of atherosclerosis, Anat Cell Biol. 49:99-106.


[15] Mishra BB. et al. (2011). Natural products: an evolving role in future drug discovery, Eur J Med Chem. 2011;46:4769–807


[16] Liu Q. et al. (2015). Chinese herbal compounds for the prevention and treatment of atherosclerosis: experimental evidence and mechanisms, Evidence-based Complementary and Alternative Medicine, article ID 752610


[17] Kruth HS. (2013). Fluid-phase pinocytosis of LDL by macrophages: a novel target to reduce macrophage cholesterol accumulation in atherosclerotic lesions, Curr Pharm Des. 19: 5865–72.


[18] Manning-Tobin JJ. et al. (2009). Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice, Arterioscler Thromb Vasc Biol. 29:19 –26.


[19] Xie C. et al. (2011). Phenolic acids are in vivo atheroprotective compounds appearing in the serum of rats after blueberry consumption, J Agric Food Chem. 59: 10381–7.


[20] Ghosh S. et al. (2010). Macrophage cholesteryl ester mobilization and atherosclerosis, Vascul Pharmacol. 52:1–10.


[21] Ghosh S. (2012). Early steps in reverse cholesterol transport: cholesteryl ester hydrolase and other hydrolases, Curr Opin Endocrinol Diabetes Obes. 19: 136–41.


[22] Xu G. et al. (2009). Preventive effects of Heregulin-